camrelizumab + apatinib mesylate + tegio

This is a three-drug combination regimen consisting of camrelizumab, apatinib mesylate, and Tegio. Camrelizumab is a humanized monoclonal antibody targeting programmed cell death protein 1 (PD‑1), functioning as an immune checkpoint inhibitor to enhance anti-tumor immune responses. Apatinib mesylate (also known as rivoceranib) is a small molecule tyrosine kinase inhibitor that selectively inhibits vascular endothelial growth factor receptor 2 (VEGFR2), thereby blocking angiogenesis in tumors. Tegio is an oral fluoropyrimidine-based chemotherapy composed of tegafur (a prodrug of 5-fluorouracil), gimeracil, and oteracil; it acts primarily by inhibiting thymidylate synthase after conversion to 5-FU, disrupting DNA synthesis in rapidly dividing cancer cells[7][10]. This triple regimen has been investigated as first-line therapy for advanced or refractory gastric cancer[2][4][8], with ongoing studies also exploring its use in other solid tumors such as hepatocellular carcinoma and esophageal squamous cell carcinoma.

Brand names

Teysuno

Other names

rivoceranibS-1S1S 1